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Immune system – Part I
Fundamentals of innate immunity with 
emphasis on molecular and cellular 
mechanisms of inflammatory response
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Alexandre Wagner Silva de Souza5, Neusa Pereira da Silva6, Luís Eduardo Coelho Andrade6
ABSTRACT
The immune system consists of an intricate network of organs, cells, and molecules responsible for maintaining the 
body’s homeostasis and responding to aggression in general. Innate immunity operates in conjunction with adaptive 
immunity and is characterized by rapid response to aggression, regardless of previous stimulus, being the organism 
first line of defense. Its mechanisms include physical, chemical and biological barriers, cellular components, as well as 
soluble molecules. The organism first line of defense against tissue damage involves several steps closely integrated and 
constituted by different components of this system. The aim of this review is to restore the foundations of this response, 
which has high complexity and consists of several components that converge to articulate the development of adaptive 
immune response. We selected some of the following steps to review: perception and molecular recognition of aggres-
sive agents; activation of intracellular pathways, which result in vascular and tissue changes; production of a myriad of 
mediators with local and systemic effects on cell activation and proliferation, synthesis of new products involved in the 
chemoattraction and migration of  cells specialized in destruction and removal of offending agent; and finally,  tissue 
recovery with restoration of functional tissue or organ.
Keywords: innate immunity, inflammation, autoimmunity, PAMPs, Toll-like receptors.
INTRODUCTION
The immune function has been conceptually divided into 
innate and adaptive immunity. Innate immunity represents a 
rapid and stereotyped response to a large but limited number of 
stimuli. It is represented by physical, chemical, and biological 
barriers, specialized cells and soluble molecules, present in all 
individuals, irrespective of previous contact with offending 
agents or immunogens, and does not change qualitatively or 
quantitatively after contact.1
 The main effector cells of innate immunity are macrophages, 
neutrophils, dendritic cells, and natural killer (NK) cells 
(Table 1). Phagocytosis, release of inflammatory mediators, 
activation of complement system proteins, as well as synthesis 
of acute phase proteins, cytokines and chemokines are the 
main mechanisms in innate immunity. These mechanisms 
are activated by specific stimuli, represented by molecular 
structures of ubiquitous occurrence in microorganisms, but not 
in human species. Molecules commonly found on the surface 
of microorganisms, such as lipopolysaccharides, mannose 
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and teichoic acids constitute pathogen-associated molecular 
patterns (PAMPs) and activate the innate immune response 
by interaction with different receptors known as pattern 
recognition receptors (PRR), among which is the family of 
Toll-like receptors (TLRs).2 This interaction is similar to the 
complementarity between antigen and antibody or between 
antigen and T-cell receptor (TCR), but in this case, there is 
no diversity or adaptive capacity to generate new receptors 
or recognition of new molecular patterns than those already 
programmed in genetic code.
 Among the various PRRs involved in opsonization, 
complement activation, and phagocytosis, the TLRs are 
distinguished by their central role in binding to pathogens 
and initiating the inflammatory response. These receptors are 
present mainly on macrophages, neutrophils, and dendritic 
cells (DCs). Currently, eleven different TLRs have been 
identified, some located in the cell membrane, others inside the 
cells (Figure 1).3 Other receptors present in phagocytes with 
important role in immune response are those for fractions of 
complement, cytokines, interleukins, and immunoglobulins 
(FcγR type).4
 Phagocytosis begins with adhesion of the phagocyte 
surface receptors to the pathogen, which then is internalized 
into vesicles called phagosomes. Inside the phagocyte, the 
phagosome fuses to lysosomes, whose contents are released 
with consequent digestion and pathogen elimination.4 
Changes in the oxidase’s gene system components present in 
phagolysosome membrane lead to disability in respiratory burst 
and generation of reactive oxygen species (ROS). The absence 
of ROS determines serious deficiency in the destructive 
capacity of phagocytes, being responsible for a significant 
primary immunodeficiency called chronic granulomatous 
disease.5
 Unlike innate response, adaptive or acquired immune 
response depends on activation of specialized cells (the 
lymphocytes) and soluble molecules produced by lymphocytes 
(Table 1). The main features of acquired response are: 
specificity and diversity of recognition, memory, specialized 
response, self-restraint, and tolerance to components of the 
organism itself. Although the main cells involved in acquired 
immune response are lymphocytes, antigen presenting cells 
(APCs) play a key role in its activation, presenting antigens 
associated with molecules of the major histocompatibility 
complex (MHC) to T lymphocyte  (TL).6 Figure 2 illustrates 
the various cells that comprise the immune system.
DENDRITIC CELLS
Dendritic cells, specialized in capturing and presenting antigens 
to lymphocytes, are considered a bridge between innate and 
adaptive immunity because they are attracted and activated by 
elements of innate response and permit TL sensibilization of 
adaptive immune response. Dendritic cells reside in peripheral 
tissues, such as skin, liver, and intestine, where they capture 
antigens and become activated and migrate to regional lymph 
nodes, in which they process and present protein antigen or 
lipid to TLs. Immature DCs are highly efficient in capturing 
antigens, while mature DCs are very efficient in presenting 
antigens.7 The captured antigens are processed inside the 
cell and presented on its surface, bound to MHC molecules. 
Generally, protein antigens are presented by MHCs classical 
molecules (class I and II) that stimulate LTαβ. Lipid antigens 
Table 1
Soluble molecules and cells of the immune system
Component Innate immunity Acquired immunity
Cells Phagocytes (dendritic 
cells, macrophages, 
and neutrophils)
Natural killer (NK)
Mast cells, eosinophils 
and basophils
NK/T, B, and T 
lymphocytes
Dendritic cells or 
antigen-presenting 
cells (APCs)
Soluble molecules Complement
Acute phase proteins
Cytokines 
Chemokines
Antibodies 
Cytokines 
Chemokines
Figure 1
Concept of pathogen associated molecular patterns (PAMPs) and 
pattern recognition receptors (PRR). Schematic representation 
of the different pattern recognition receptors anchored in the 
cell membrane and their respective ligands (PAMPs).
TLR Peptide receptor for 
N-methyl-formylated
Mannose 
receptor
Scavenger 
receptor
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are presented by MHCs non-classical molecules as CD1 and 
stimulate primarily LTγδ and NK/T.
 During their lifetime, the immature DCs migrate from 
bone marrow into bloodstream, reaching peripheral tissues 
as skin, where they become residents (Langerhans cells). A 
curious aspect is that DCs are the first cells to arrive at a site 
of infection, preceding even the neutrophils. After contact 
with antigen, DCs become activated and migrate through 
lymphatic vessels to secondary lymphoid organs (Figure 
3). They can receive signals from mature NK, NK/T, and 
TL cells, and proinflammatory molecules such as cytokines, 
prostaglandins, interferons, and PAMPs.7 DCs retain antigen in 
lymphoid organs for extended periods, which may contribute to 
immunological memory.8 These cells orchestrate the migration 
of other types of immune cells within the lymph nodes via 
secretion of chemokines and regulate the differentiation, 
maturation, and function of TL in a contact-dependent mode 
and by secretion of soluble factors. Therefore, DCs are essential 
for the initiation and coordination of the acquired immune 
response.7
 There are two pathways of DCs differentiation from a 
common progenitor. The myeloid pathway generates myeloid 
DCs (mDCs), among which there are the Langerhans cells, the 
main DCs in skin, and the interstitial DCs found in other tissues. 
The other pathway of differentiation generates plasmacytoid 
DCs (pDCs), which predominate in the peripheral blood and 
secrete large amounts of type I interferon (IFN-α/β) in the 
presence of viral infections. The pDCs have receptors capable 
Figure 2
Source of several cell lines of immune system.
Figure 3
Dendritic cells and generation of TLs specific antigens. 
(A) Characteristics of immature dendritic cells (iDCs). 
(B) Activation and uptake of pathogens through cytokine 
microenvironment and interaction with pattern recognition 
receptors, with consequent migration of DCs to lymph nodes. 
(C) Maturation of dendritic cells. (D) Migration of naive T 
cells to paracortical area of lymph node. Entry through high 
endothelial venules (HEV) and chemokine-driven migration 
of lymphoid tissue. (E) Presentation of processed antigens to 
T lymphocytes, generating activated effector cells.
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of responding to RNA (TLRs 7 and 8) and DNA (TLR9), 
whereas mDCs preferentially express surface receptors for 
PAMPs, such as peptidoglycan (TLR2) and lipopolysaccharide 
(TLR4).9 
 DCs are crucial for determining the activation and type 
of immunity mediated by TLs. In general, immature DCs 
are tolerogenic, while mature DCs are immunostimulatory. 
However, in some contexts, mature DCs can expand the 
population of TLs regulators. Induction of tolerance or immune 
response depends on the set of signals received by DCs, such as 
activation of TLRs and cytokines present in the environment.10 
DCs can coordinate LBs response via TL activation or directly 
by soluble substances such as INF-α.7
NEUTROPHILS
Neutrophils are the most abundant leukocytes in peripheral 
blood, with an important role in the early stages of inflammatory 
reaction and sensitive to chemotactic agents, such as cleavage 
products of complement fractions (C3a and C5a) and 
substances released by mast cells and basophils. They are 
among the first cells to migrate from vessels to tissues attracted 
by chemokines, such as IL-8, and are activated by various 
stimuli, such as bacterial products, complement proteins (C5a), 
immune complex (IC), chemokines, and cytokines.
 The neutrophil phagocytic capacity is stimulated by 
binding of its receptors for opsonins, IgG-Fc, C3b, and TLRs. 
These cells also undergo degranulation, releasing three classes 
of granules in the extracellular environment:
Primary or azurophilic granules that contain important 
mediators, such as myeloperoxidase, defensins, neutrophil 
elastase, permeability-increasing protein, and bacterial 
cathepsin G.
Secondary granules with components specifically secreted 
by neutrophils, with lactoferrin is a prime example.
Tertiary granules with cathepsins and gelatinases as main 
proteins.
Recent studies have shown that neutrophils can also 
generate the so-called neutrophil extracellular traps (NETs) 
formed by granule substances and nuclear components 
capable of calling off the virulence factors and destroying 
extracellular bacteria. The NETs are present in large quantity 
in inflammatory sites, acting directly on microorganisms and 
also serving as a physical barrier that prevents spreading.11
Under normal conditions, neutrophils are cleared from the 
circulation and inflamed tissues by apoptosis. Disturbances 
in these cells apoptosis have been associated with several 
autoimmune conditions, especially SLE, as circulating 
apoptotic debris containing nuclear material could lead to the 
induction  of a huge variety of autoantibodies.11
MACROPHAGES
Monocytes constitute 3-8% of circulating leukocytes and, 
in connective tissue or parenchyma of organs, give rise to 
macrophages and myeloid dendritic cells. Monocytes and 
macrophages are efficient phagocytes, engulfing pathogens and 
cellular debris. Unlike neutrophils, macrophages can remain 
in tissue for months to years, acting as true sentinels. Besides 
having a role in innate immunity, macrophages process and 
present antigens via MHC molecules, thus stimulating the 
response mediated by TL.4 
 Recently, the existence of three subpopulations of 
macrophages was proposed: activated, tissue repair, and 
regulator macrophages. The first would be the classic 
macrophages with tumoricidal and microbicidal activity, 
which secrete large amounts of proinflammatory mediators 
and cytokines, present antigens to TLs, and are involved in 
cellular immune response. The second type, activated by IL-
4, would be primarily involved in tissue repair by stimulating 
fibroblasts and promoting extracellular matrix deposition. The 
third type would exert regulatory activity through release of 
IL-10, an anti-inflammatory cytokine.13
 In inflammation, macrophages act as APCs, potentiating 
the activation of TL and LB by the expression of coestimulatory 
molecules, and release proinflammatory cytokines, such as 
IL-1, IL-6, IL-12, TNF-α, and chemokines. They also produce 
reactive oxygen species (ROS), such as superoxide anion, 
hydroxyl radical, hydrogen peroxide (H2O2), and reactive 
nitrogen intermediates whose main representative is nitric 
oxide (NO). NO is produced by inducible nitric oxide synthase, 
iNOS, absent in resting macrophages, but induced by TLRs 
activation in response to PAMPs, especially in the presence 
of INF-γ.4
 Some microorganisms, like Mycobacterium tuberculosis, 
are resistant to the microbicidal action and remain viable for a 
long time in macrophages’ phagosomes . These macrophages 
become large and multinucleated (giant cells) and, together 
with lymphocytes and fibroblasts that accumulate around them, 
form granulomas, which are the body’s attempt to prevent the 
spread of the pathogen.
NATURAL KILLER CELLS
Natural killer cells (NK) originate in bone marrow from a 
common progenitor to TLs, constituting 5% to 20% of blood 
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mononuclear cells. They are an important line of nonspecific 
defense, recognizing and lysing cells infected by viruses, 
bacteria and protozoa, as well as tumor cells. Furthermore, 
they recruit neutrophils and macrophages, activate DCs and 
T and B lymphocytes.14
 The expansion and activation of NKs are stimulated by 
IL-15, produced by macrophages, and IL-12, potent inducer 
of IFN-γ and cytolytic action. Once activated, the NKs lyse 
infected and tumoral cells and secrete proinflammatory 
cytokines (IL-1, IL-2, and especially IFN-γ).14
 The cytolysis mediated by NKs occurs through the action 
of the enzymes perforins, which create pores in membrane 
of target cells, and granzymes, which penetrate into cells 
and trigger cell death by apoptosis. NK cells have activation 
and inhibition receptors, and the balance between the signals 
generated by these receptors determines NK activation. One 
class of receptors belongs to the immunoglobulin superfamily 
(KIR), while the other belongs to the family of C-type 
lectins. In humans, there are 14 KIRs, eight activators and six 
inhibitors.15 The inhibitory receptors recognize the self MHC 
class I molecules, expressed on the surface of all nucleated 
cells. In general, there is dominance of inhibitory receptors, 
preventing lysis of host’s normal cells that express MHC 
class I. Infected cells, especially by viruses, and tumor cells 
often have low expression of MHC class I proteins, becoming 
vulnerable to the action of NK (Figure 4).15 The tumoricidal 
capacity of NK is increased by cytokines, such as interferons 
and interleukins (IL-2 and IL-12). Another effector action of 
NK is the destruction of cells coated with IgG, via Fc receptors 
(FcγRIII or CD16), by a mechanism of antibody-dependent 
cellular cytotoxicity (ADCC).14
MAST CELLS
Mast cells are derived from CD34+ hematopoietic progenitors 
in bone marrow and, in general, are not found in the circulation. 
From bone marrow, the progenitors migrate to peripheral 
tissues as immature cells and differentiate in situ according 
to the particular characteristics of the microenvironment.16.17 
Mature mast cells are distributed strategically along the 
blood vessels, nerves, and under the epithelium of skin 
and mucous membranes; they are particularly abundant in 
areas of environment contact and play a key role in acute 
inflammatory reactions.18 Mast cells have surface receptors 
of high affinity, FcεRI, bound to IgE molecules, and are 
activated by multivalent antigen recognition by IgE. Stimuli 
such as products of complement activation, basic substances, 
including some animals’ poisons, certain neuropeptides, and 
several physical agents (mechanical trauma, heat, and cold) 
can activate mast cells independently of IgE binding. The 
binding of bacterial components to TLRs 1, 2, 4, and 6, and 
other specific receptors such as CD48, also activates mast cells, 
leading to mediators’ release .
 The classic example of mast cells involvement in 
inflammatory processes are the reactions in which they, 
together with its circulating equivalent, basophil, in contact 
with the allergen trigger a type I hypersensitivity reaction 
via FcεRI activation. After the stimulus, degranulation and 
release of preformed mediators occur, followed by the release 
of newly formed mediators. Preformed mediators include 
vasoactive amines, proteases, heparin, IL-4, TNF-α, and GM-
CSF (Granulocyte-Macrophage Colony-Stimulating Factor). 
The mediators formed following activation include platelet 
Figure 4 
Function of receptor activation (ITAM) and inhibition (ITIM) 
in the physiology of NK cells. (A) Interaction of NK cells with 
a normal body cell expressing MHC class I, with consequent 
inhibition of NK cytolysis dependent induction. (B) Interaction 
of NK cells with virus-infected cell, with consequent MHC 
class I loss of expression, which results in activation of NK 
cells with concomitant release of lethal products.
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Normal cell with MHC class I expression
Cell without MHC class I expression
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activating factor (PAF), arachidonic acid derivatives, and a 
series of cytokines.4 The release of these mediators induces 
inflammatory cell migration (neutrophils and macrophages), 
increased vascular permeability, mucus secretion, increased 
gastrointestinal motility, and bronchoconstriction, which are 
the signs and symptoms of allergy and anaphylaxis.19
 Chronic Idiopathic urticaria is mainly caused by 
degranulation of mast cells, and in 25% to 50% of cases auto-
antibodies directed against the FcεRIα receptors are found and, 
less frequently, against IgE itself. These autoantibodies cause 
histamine release and characterize the chronic autoimmune 
urticaria, with clinical and histological features similar to those 
found in a late-phase reaction.4
 There is experimental evidence of mast cells involvement 
in cardiovascular diseases, neoplastic diseases, parasitic 
and bacterial infections, fibrotic diseases, and autoimmune 
diseases.20 Several histological studies have reported the 
presence of mast cells in normal human synovium and 
expansion of this population in rheumatoid arthritis, gout, 
osteoarthritis, among others.21 Effector functions of mast cells 
in synovia suggest their involvement in leukocyte recruitment, 
fibroblast activation and hyperplasia, angiogenesis, and 
destruction of cartilage and bone.22 They also participate in 
joint destruction by inducing fibroblasts and chondrocytes to 
secrete matrix metalloproteinases and promoting osteoclast 
differentiation. In fact, the involvement of mast cells with 
chemotactic activity has been reported in various autoimmune 
clinical conditions, including rheumatoid arthritis, Sjögren’s 
syndrome, systemic sclerosis, autoimmune thyroid diseases, 
chronic urticaria, pemphigus, and atherosclerosis.23
BASOPHILS
Basophils are granulocytes derived from progenitors in bone 
marrow, where they mature and make up less than 1% of 
peripheral blood leukocytes. Although not normally present in 
tissues, they can be recruited to inflammatory sites, together 
with eosinophils. The granules found in basophils have 
mediators similar to those of mast cells. Basophils also express 
FcεRI, bind IgE, and are activated by IgE-antigen complexes 
and may contribute to immediate hypersensitivity reactions.24
EOSINOPHILS
Granulocytes and eosinophils are important infection-fighting 
cells, and their antiparasitic action (helminths) is one of the 
most powerful and effective. They are also important in allergic 
reactions and asthma. Eosinophils develop in the bone marrow, 
producing and storing various secondary proteolytic granules 
before leaving the marrow. After maturation, they circulate 
through the bloodstream in small amounts and can be found in 
greater numbers in mucosal regions, such as gastrointestinal, 
respiratory, and genitourinary tracts.4 Eosinophils are recruited 
to sites of parasitic infections and allergic reactions by adhesion 
molecules and chemokines.24 They fight parasitic infections 
by antibody-dependent cell-mediated cytotoxicity, with FcεRI 
receptor participation. During this process, they adhere to 
pathogens coated with IgE (or IgA) and release their granular 
content after FcεRI receptors bind to IgE bound to the target 
antigen. Once activated, eosinophils induce inflammation 
through production and release of eosinophilic cationic content 
of granules. The main components of these granules are: 
major basic protein, eosinophil cationic protein, eosinophil 
derived neurotoxin, and eosinophil peroxidase, which have 
great potential cytotoxicity on parasites, but also can cause 
tissue injury. Eosinophil cationic protein and neurotoxin 
are ribonucleases with antiviral properties. The major basic 
protein presents toxicity to parasites, induces degranulation 
of mast cells and basophils, and activates the synthesis of 
remodeling factors by epithelial cells. Eosinophil cationic 
protein creates pores in target-cell membrane, allowing the 
entry of other cytotoxic molecules; inhibits TL proliferation; 
suppresses antibody production by LB; induces degranulation 
of mast cells; and stimulates secretion of glucosaminoglycans 
by fibroblasts.
Eosinophil peroxidase forms ROS and NO, promoting 
oxidative stress in target-cell and causing cell death by 
apoptosis and necrosis.25 Other effector mechanisms that 
contribute to the inflammatory process include production of 
a variety of cytokines, such as IL-1, IL-2, IL-4, IL-5, IL-6, 
IL-8, IL-13, and TNF- α,25 and release of proinflammatory 
lipid mediators, such as leukotrienes (LTC4, LTD4, LTE4), 
and prostaglandins (PGE2). Elastase enzymes and the growth 
factor TGF-β, growth factor derived from platelets (PDGF), 
and endothelial vessels growth factor (VEGF) contributes to 
tissue remodeling.
THE COMPLEMENT SYSTEM
Complement system (CS) consists of a family of more than 
20 plasma glycoproteins, synthesized in the liver, but also by 
macrophages and fibroblasts. Each SC activated component 
acquires proteolytic activity activating the next elements 
in cascade. Throughout the process, there is the production 
of several mediators that alter vascular permeability and 
contribute to the development of inflammatory response. 
Cruvinel et al.
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Finally, there is formation of membrane attack complex 
(MAC), which promotes osmotic lysis of target-cell, favoring 
the elimination of the infectious agent.4
 There are three forms of CS activation: classical, 
alternative, and via mannose-binding lectin (MBL). The 
activation of these pathways contributes to the integration 
of effector mechanisms of innate and adaptive immunity 
(Figure 5). In the innate immune response, pathogens that 
invade the organism encounter soluble substances of innate 
immune response, such as CS proteins, C-reactive protein, 
and others. In adaptive immunity, CS is activated by binding 
of preformed antibodies to pathogen or antigen (immune 
complex).26 Lectin pathway begins by recognizing mannose 
on microorganism surface by MBL bound to MASP1 and 
MASP2 serine proteases. Activation of these proteases results 
in the breakdown of CS components C2 and C4 into smaller 
fragments (C4a and C2b) and larger fragments (C4b and 
C2a). C4bC2a complex is the C3 convertase of the classical 
pathway, which cleaves C3 into soluble C3a and C3b, which 
in turn binds to C4bC2a at the surface of microorganism. The 
C4bC2aC3b complex, called C5 convertase, cleaves the C5 
component, following on this pathway and culminating in the 
formation of MAC. The classical pathway resembles the lectin 
pathway and is initiated by the binding of C1q component to 
two molecules of IgG or to one molecule of IgM, complexed 
with the target antigen (immune complexes). This binding 
activates the proteases R (C1r) and S (C1s) associated with 
C1q, cleaving components C2 and C4 and following the 
pathway, as described. Because the classical pathway depends 
on the prior production of specific antibodies attached to the 
surface of pathogens, it is associated with specific humoral 
immune response.26
 The alternative pathway begins with the spontaneous 
rupture of the C3 component into C3a and C3b fragments 
(Figure 5). A thioester binding in fragment C3b is exposed 
with this cleavage, which allows their covalent binding to the 
surface of invading microorganisms. If there is no binding of 
C3b component, thioesters binding site is rapidly hydrolyzed 
and the fragment is inactivated. The binding of C3b enables 
binding to Factor B, which is then cleaved into fragments Ba 
and Bb by Factor D. The C3bBb complex (alternative pathway 
C3 convertase) cleaves more C3 molecules and remains on the 
surface. This complex is stabilized by properdin (Factor P), 
amplifying the breakdown of C3. C3bBb component cleaves 
C3, generating C3bBbC3b, a protease able to cleave C5, the last 
step of the alternative pathway.26 Lectins pathways, classic and 
alternative, have in common the formation of C5 convertase, 
which promotes cleavage of C5 component and generates 
fragments C5a and C5b. The binding of C5b to pathogen 
surface initiates the formation of membrane attack complex 
by binding successive components C6 and C7 in the lipid 
bilayer of the cell membrane. The C5b,6,7 complex allows the 
binding of C8 component and, finally, there is polymerization 
of C9 crossing the lipid bilayer and promoting osmotic lysis 
of infectious agent.
Smaller fragments released during the cascade have 
important biological effects. C2a and C4a are related to 
changes in vascular permeability; Bb is related to activation 
of macrophages; C3a, C4a, and C5a induce activation of 
mast cells and neutrophils; and C5a stimulates motility and 
adhesion of neutrophils to inflammatory foci. The fragments 
C3b and C4b function as opsonins, enhancing the process of 
phagocytosis by interaction with the complement receptor CR1 
on phagocyte surface. The CR1-C3b interaction also promotes 
the clearance of immune complexes, which are carried by red 
blood cells and removed by phagocytes in the liver and spleen.26
Regulation of CS activation is promoted by both circulating 
soluble proteins and proteins bound to the cell membrane. This 
Figure 5
The three pathways of the complement system.
Pathways of Mannose-Binding Lectins (MBL)
I. Binding of MBL complex (MASP 1 and 2) to 
bacterial surface and breakdown induction of 
components C4 and C2, generating C4a and C2b 
soluble fragments and C4a and C4b fragments 
(membrane).
II. Insertion of components C4bC2a in pathogen 
membrane and C3 convertase formation, which 
promote component C3 cleavage, generating 
soluble fragment C3a and solid fragment C3b.
III. Binding of C3b to membrane and complex 
C4b2a forming C5 convertase, which will promote 
cleavage of component C5.
ALTERNATIVE PATHWAY
I. Binding of C3b to bacterial surface, from classical and MBL pathways, or process of spontaneous hydrolysis of 
C3 component.
II. Binding of factor B to C3b which is then cleaved by factor D, generating soluble fragments Ba and Bb.
III. Binding of Bb fragment to C3b forming C3 convertase of alternative pathway, which promotes proteolytic 
cleavage of component C3. Generation of C3a and C3b fragments.
IV. Binding of C3b fragment to C3bBb forming C5 convertase of alternative pathway, which will promote cleavage 
of C5 component (common pathway).
Common Pathway
IV. Action of C5 convertase on C5 component 
generating the soluble fragment C5a and C5b that 
adheres to the membrane.
V. Binding of soluble components C6 and C7 and 
assembly of receptor (C5bC6C7) for C8 component 
binding. Insertion into membrane.
VI. Binding of C9 component with consequent 
polymerization generating membrane attack complex 
(MAC).
In activation of Classical Pathway, the binding of 
antibodies to the surface of pathogen occur previously, 
which will be bound by the complex C1qRS that will 
promote cleavage of components C2 and C4.
Pathways of Lectins
ALTERNATIVE PATHWAY
C3 Convertase
C3 Convertase
C5 Convertase
C5 Convertase
Common Pathway
Common Pathway
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mechanism is species-specific, ensures that the activation of 
CS at low levels does not impair the organism’s own cells, 
and prevents the occurrence of deposition of the complexes 
generated on autologous cells.
THE MAJOR HISTOCOMPATIBILITY COMPLEX
The human major histocompatibility complex (MHC) is 
composed of a set of highly polymorphic genes called human 
leukocyte antigen (HLA) and comprises more than 120 
functional genes, of which about 20% are associated with 
immunity. The association between autoimmune diseases 
and MHC genes reflects the important role of these molecules 
in directing the immune response. For its role in antigen 
presentation, MHC provides a link between innate response 
and adaptive response.8 In humans, these genes are located 
on chromosome 6 and are traditionally divided into classes 
I, II, and III.27 Only the genes of classes I and II are involved 
in presenting antigen protein to LT. Class I molecules are 
present on the surface of all nucleated cells, while class II 
are found primarily on APCs (macrophages, DCs, and LB). 
All MHC molecules found in the surface of a cell have an 
associated peptide. Although the molecules of classes I and II 
exhibit different structural characteristics, both are expressed 
as heterotrimers in which two chains are from MHC molecule 
and the third is the peptide presented to TL (Figure 6 C).8 
There are about 20 genes in HLA region class I, and three of 
them (HLA-A, B, and C) are called classics (Figure 6A). The 
genes that encode the classical MHC molecules are highly 
polymorphic. Class I molecules have one α-chain encoded by 
the genes HLA-A, B, or C, and a small invariant chain, the β2-
microglobulin. Because these genes have codominance, each 
individual may have three to six different types of HLA class 
I on the surface of his cells, encoded by maternal and paternal 
alleles of the HLA-A, B, and C genes.8 Class I molecules 
present endogenous peptides to CD8 TLs, i.e., peptides derived 
from autologous proteins in cytoplasm.
 HLA class II molecules consist of two chains, α and 
β, both encoded by polymorphic genes in MHC class II 
complex regions (Figure 6 B). The α and β chains of class 
II molecules are encoded by genes HLA-DR, DP, and DQ 
families. Typically, an α chain of any type (for example, DR 
type) is associated with a β chain of the same type, but there 
may be heterologous pairing; thus, depending on the degree of 
homozygosity or heterozygosity, an individual may develop on 
the surface of his APCs 10 to 20 different class II molecules. In 
the nomenclature of genes in class II, the first letter indicates 
the class (D), the second indicates the family (M, O, P, Q, R) 
and the third class indicates the chain A (α) or B (β). Individual 
genes of each of these families are distinguished by numbers, 
and complete nomenclature of an allelic variant is preceded by 
an asterisk. For example, HLA-DRB1*0101 means the 0101 
allele of gene 1 encoding the β chain of class II molecule of the 
DR family (Figure 6 D). The HLA class II molecules present 
exogenous peptides to TL, i.e., derived from proteolysis of 
non-autologous proteins in phagolysosomes.
INNATE IMMUNITY IN THE CONTEXT 
OF INFLAMMATORY RESPONSE
The first line of defense of the organism to tissue damage 
is an inflammatory response, a complex biological process 
that involves vascular and cellular components and a variety 
of soluble substances, besides having characteristic clinical 
signs, such as redness, warmth, swelling, pain, and functional 
Figure 6
Relative genomic position of genes within the HLA region of 
chromosome 6 short arm, which contains the human MHC 
Class I (A) and II (B). Peptide chains molecules of MHC class 
I and class II (S). Roadmap for the nomenclature interpretation 
of specificity and alleles of the major histocompatibility 
complex - MHC (D).
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impairment. The purpose of this process is to remove the 
stimulus inducing the response and start local tissue recovery.4 
When inflammation is taking place, several biochemical 
systems, such as CS and coagulation cascades, are activated 
to help the establishment, development, and resolution of the 
process. Additionally, short half-life soluble substances are 
released, which exert their action and are degraded. Typically, 
the successful removal of the triggering stimulus leads to the 
resolution of acute response and complete tissue repair.
 The acute inflammatory response evolves from a phase 
started by vascular cells in the tissue immediately after the 
injury. At baseline, only a fraction of the capillaries comprising 
the tissue is permeable, but after injury, local vasodilation and 
increased capillary permeability occur mediated by vasoactive 
amines, histamine, and serotonin released from mast cells 
and monocytes minutes after the injury. Initially, electrolytes 
and small molecules leave the capillary bed, forming the 
transudate. Subsequently, larger molecules, such as albumin 
and fibrinogen, also leave the capillary bed, forming the 
exudate. Protein output to extravascular space is accompanied 
by water loss and marginalization of leukocytes, which start 
circulating by the endothelium. The local endothelium becomes 
activated, expressing surface molecules that promote adherence 
of leukocytes and their eventual migration to the tissues. Some 
components of CS, kinins generating system, and coagulation 
system also leave to the extravascular space and are activated. 
Macrophages in the injured tissue release inflammatory 
cytokines, such as IL-1, TNF-α, and chemokines.28
 Migration of circulating cells into tissues, called 
diapedesis, is directed by the presence of a gradient of 
chemotactic substances in the inflammatory site. When 
these cells are present in tissue, they seek the phagocytosis 
of pathogen, allowing the tissue repair (Figure 7). In acute 
inflammation, the predominant elements of the innate immune 
response and the principal cells involved are neutrophils and 
macrophages. In chronic inflammation, usually caused by 
persistent noxious stimulation, the inflammatory process is 
maintained and undergoes qualitative changes, characterized 
by progressive change in soluble and cellular elements that 
infiltrate the tissue.4 Persistence of harmful agent leads to the 
chronicity of the process, with concomitant destruction and 
tissue repair. In chronic inflammation, tissue characteristically 
presents an infiltrate composed mainly of mononuclear 
cells (monocytes, macrophages, and lymphocytes), signs of 
angiogenesis, and fibrosis (Table 2). Several stimuli can induce 
persistent chronic inflammation, such as intracellular bacteria 
(e.g., Mycobacterium tuberculosis), chemical substances 
such as silica, and even physical agents such as ultraviolet 
radiation, and repetitive trauma. The mechanisms involved 
in chronic systemic inflammation of unknown etiology, such 
as rheumatoid arthritis, are not as well understood as those 
associated with infectious processes.29
LEUKOCYTE MIGRATION: 
ADHESION MOLECULES
In normal blood flow conditions, the cells circulate in the 
center of the vessels, where the resistance is lower and flow 
rates are higher. When there is vasodilation, the rate of blood 
flow decreases and the circulating cells collide more often with 
Figure 7
Mechanisms of leukocyte migration to inflammatory site. 
Macrophages stimulated by inductors of inflammatory 
response produce cytokines, such as TNF-α and IL-1, which 
induce the endothelial venules to express selectins, integrins, 
and chemokines ligands . Selectins mediate the weak adhesion 
of neutrophils; integrins promote strong adhesion; and 
chemokines activate and stimulate the migration of neutrophils 
to inflammatory focus. Monocytes and activated T lymphocytes 
use the same mechanisms to migrate to infection sites.
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activated endothelial cells, which express surface molecules 
capable of binding to leukocytes. The activated endothelial 
cells express high levels of adhesion molecules of the selectin 
family, intercellular adhesion molecule 1 (ICAM-1), and 
vascular cell adhesion molecule 1 (VCAM-1). Endothelial 
activation is caused by microbial products, cytokines (IL-
1, TNF-α), CS activated components, coagulation factors, 
histamine, and leukotriene B4.4 Selectins are glycoproteins 
present in leukocytes (L-selectin), endothelium (E-selectin and 
P-selectin), and platelets (P-selectin) that bind glycosylated 
molecules on other cells surface and, typically, mediate 
adhesion of low affinity between leukocytes and endothelium.4 
Despite the low affinity, this interaction is sufficient to attract 
leukocytes to the periphery and promote contact with the 
endothelium.
Taking a neutrophil as an example, its first contact with 
the activated endothelium is mediated by interaction of 
selectins P and E on endothelium with mucin present on its 
surface. Concomitantly, L-selectin constitutively expressed on 
neutrophils binds to the set of mucin on endothelium surface. 
These are rapid dissociation bindings, which causes neutrophils 
to roll in the vessel wall driven by blood flow and being exposed 
to chemotactic factors.  Among the chemotactic factors, we 
highlight the fragments of fibrin; collagen; platelet soluble 
factors; mediators from mast cells C5a, C3a, and C4a; residues 
of bacterial metabolism, such as N-formylated peptides; and 
chemokines secreted by different cell types.30 Chemokines 
induce changes in another set of adhesins on leukocyte surface, 
integrins, leading to recognition of higher avidity to ligands 
expressed on endothelial cells, immobilizing neutrophils and 
promoting their adherence to the vessel wall. The migration 
of cells attached to the adjacent tissue is driven by the 
increasing gradient of chemotactic products, facilitated by the 
interaction of integrins with extracellular matrix components, 
such as fibrin and fibronectin. Leukocyte extravasation and 
migration depend on the chemokines IL-8 and MCP-1, which 
are produced at infection sites and bind to proteoglycans on 
extracellular matrix and similar molecules on endothelial cells 
surface. The IL-8, released by activated macrophages, attracts 
neutrophils that are stimulated to penetrate the inflamed tissue, 
whereas MCP-1 recruits monocytes, T cells, NK cells, and 
dendritic cells later.4 In Figure 7, some adhesion molecules and 
their ligands are outlined.30 Dynamics of adhesion molecules 
dynamics varies from minutes to hours. Some molecules, such 
as P selectin, are found in the membrane of intracytoplasmic 
secretory vesicles (Weibel-Palade bodies), which rapidly fuse 
with plasma membrane when the cell is stimulated. Others, 
such as E selectin, ICAM-1, and VCAM-1 require hours for 
their synthesis.
SOLUBLE MEDIATORS OF 
INFLAMMATORY RESPONSE
The mediators of inflammatory response are varied and derive 
from precursor cell and plasma, which can be classified 
according to their biochemical properties in: vasoactive amines, 
vasoactive peptides, cleavage of CS lipid mediator products, 
cytokines, chemokines, and proteolytic enzymes (Tables 3 
and 4). Histamine exerts its physiological effects through 
interaction with four different target cell receptors, H1, H2, H3, 
and H4. H1 promotes smooth muscle contractions of various 
organs and increase venous capillary permeability (drug 
generically known as anti-histamine receptor blockers). H2 
increases secretion of gastric acid and promotes smooth muscle 
relaxation. H3 is involved in negative feedback synthesis of 
histamine H4 and mediates mast cell chemotaxis.31
 Bradykinin is part of the peptide family, generated in 
plasma by the action of enzymes on kininogens. Bradykinin 
B2 receptors are constitutive and mediate the increased blood 
flow and vascular permeability, bronchoconstriction, and 
algetic receptor stimulation. B1 receptors, little expressed in 
most tissues under normal conditions, are rapidly induced in 
pathological conditions by various proinflammatory stimuli, 
such as IL-1, IFN-γ, and TNF-α.32 Another group of important 
molecules in  inflammatory process are the neuropeptides, 
Table 2
Characteristics of acute and chronic inflammatory processes
Inflammation
Acute Cronic
Causal agent Organic pathogens, 
ionizing radiation, 
chemical agents, 
mechanical trauma
Initial inflammatory 
stimulus persistency, 
autoimmunity
Cells involved Neutrophils, monocytes, 
macrophages, mast cells
Macrophages, 
lymphocytes, fibroblasts
Primary mediators Vasoactive amines, 
eicosanoids, 
chemokines, reactive 
oxygen species
IFN-γ, cytokines, 
growth factors, 
hydrolytic enzymes
Onset Immediate Late
Duration Few days Months or years
Evolution Healing with ad 
integrum restitution, 
abscess formation 
or chronification
Tissue destruction 
and fibrosis
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substance P, neurokinin A, vasoactive intestinal peptide (VIP), 
calcitonin gene-related peptide (CGRP), somatostatin, and 
enkephalins. Substance P and CGRP have proinflammatory 
effects and are responsible for neurogenic inflammation. 
Substance P and neurokinins act on NK1 receptors, increasing 
blood flow and vascular permeability, and on NK2 receptors, 
inducing bronchoconstriction.33
 Lipid mediators derived from arachidonic acid are 
produced by activation of phospholipases, which cleave 
phospholipids constituents of cell membrane generating 
prostaglandins, leukotrienes, and platelet-activating factor 
(PAF). Prostaglandins have functions as inflammatory fever, 
hyperalgesia, and vasodilatation, increasing edema and 
contraction or relaxation of smooth muscle. These mediators 
also participate in physiological processes, such as maintaining 
mucosal epithelium integrity, renal function, reproduction 
(fetus survival, egg implantation, uterus contraction during 
delivery), proliferation, and cell death.34
 Inflammation provides essential signals for TL and LB 
activation, thus initiating the specific immune response and 
contributing to the integration of innate and acquired immunity.
CHEMOKINES
Chemokines are a large family of homologous cytokines 
structurally responsible for the movement of leukocytes, 
including their migration from the blood to sites of tissue 
Table 4
Soluble mediators of cell derived inflammations
Cell mediators Type Main source function
Histamine Vasoactive amine Mast cells, basophils, platelets
Present in preformed granules. 
Causes arterioles dilation and 
increased vascular permeability.
Nitric oxide Soluble gas Macrophages, endothelial cells
Potent vasodilator, relaxes 
smooth muscle, reduces platelet 
aggregation, has antimicrobial 
activity at high concentrations.
Leukotriene B4 Eicosanoid derived from arachidonic acid by action of lipoxygenase Leukocytes
Promotes leukocyte activation and 
adhesion to endothelium and its 
migration. Induces formation of reactive 
oxygen species in neutrophils.
Prostaglandins Eicosanoid derived from arachidonic acid by action of cyclooxygenase Mast Cells and Basophils Cause vasodilation, fever and pain.
TNF-α  and IL-1 Cytokines Macrophages
Activate fibroblasts and promote 
leukocyte and chemotaxis adhesion. 
Cause systemic effects, including fever, 
loss of appetite and increased heart rate.
IFN-γ Cytokines  T and NK cells
Antiviral, immunoregulatory and 
antitumoral. Also called macrophage-
activating factor, is important 
in chronic inflammation.
IL-8 Chemokine Macrophages Neutrophil activation and chemotaxis.
Table 3
Soluble mediators of inflammation 
derived from plasma components
Plasma mediators Source function
Bradykinin Kallikrein-
kinin system
Vasoactive peptide causing 
vasodilatation, increased 
vascular permeability, and 
stimulation of pain-endings.
C3 and C5 Complement 
system
C3a and C5a stimulate 
histamine release, C3b 
acts as opsonin, and 
C5a has chemoattractant 
action for phagocytes.
Factor XII 
(Hageman Factor)
Liver Activated by contact in 
injured tissue, activates 
kallikrein-kinin, coagulation, 
and fibrinolytic system.
Plasmin Fibrinolytic system Enzyme capable of 
breaking fibrin clots, C3 
component of complement, 
and activate factor XII.
Thrombin Coagulation system Promotes fibrinogen 
breakdown into fibrin and 
binds to receptors that lead to 
production of inflammatory 
mediators, such as 
chemokines and nitric oxide.
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inflammation. They are small polypeptides of 8 to 12kDa with 
two internal disulfide bonds. About 50 different chemokines 
have been identified and classified into families by the number 
and location of N-terminal cysteine residues. The two main 
families are CC chemokines with adjacent cysteine residues 
and CXC family, such as IL-8, where these residues are 
separated by one amino acid.35
 Chemokines can be constitutive or induced. Constitutive 
chemokines are normally produced in various tissues and 
recruit leukocytes, mainly lymphocytes, in the absence of 
inflammation. Induced chemokines (or inflammatory) are 
produced by various cells in response to inflammatory stimuli 
and recruit leukocytes to inflammation sites.36 
Chemokine receptors have seven transmembrane domains 
coupled to G proteins, which are present on the cell surface. It 
has been identified 11 different receptors for CC chemokines 
(CCR1 to CCR11) and seven for CXC chemokines (CXCR1 to 
CXCR7). These receptors may be specific to a given chemokine 
(e.g., CCR6, CCR9, and CXCR6), but commonly a single 
receptor can bind several chemokines of the same group.35
Chemokines play a crucial role in mononuclear cells 
movement through the body and in their migration to 
tissues, contributing to the adaptive immune response and/
or pathogenesis of many diseases. Chemokine receptors are 
expressed on leukocytes, dendritic cells, and Langerhans cells. 
The greatest variety of receptors is observed in TL and its 
expression can define the migratory pattern and even facilitate 
the identification of certain subtypes of TL. The chemokine-
receptor binding initiates a complex signaling cascade that 
generates chemotactic responses, degranulation, release of 
ROS, and alteration in the affinity of integrins present on cell 
surface.36
In addition to chemotactic agents for leukocytes, 
chemokines and their receptors play other important roles. 
Some receptors, including CCR5, are the main coreceptors for 
certain strains of human immunodeficiency virus (HIV). The 
deletion of 32 nucleotides at polymorphic variant CCR5Δ32 
makes their carriers resistant to HIV infection.37
Some chemokines are involved in angiogenesis by its 
chemotactic effect on endothelial cells, while others exert 
antiangiogenic effect. It is believed that chemokines also 
play an important role in hematopoiesis, tumor cell growth, 
and development of metastases.38 Chemokines and their 
receptors have also been implicated in the pathogenesis of 
several neurological diseases, including multiple sclerosis.39 
Elevated levels of IL-8 have been reported in synovial tissue 
and synovial fluid in cases of rheumatoid arthritis and various 
systemic inflammatory conditions.40
INFLAMMATORY RESPONSE CLASSIFICATION
The inflammatory response is generally beneficial to the body, 
resulting in elimination of microorganism by phagocytosis 
or lysis by CS, dilution or neutralization of toxic or irritants 
irritating substances by local leakage of fluid rich in proteins, 
and limitation of initial injury by fibrin deposition. In some 
situations, however, it may have undesirable consequences; 
for example, in allergic reactions and autoimmune diseases. 
The exacerbated inflammatory responses mediated by the 
immune system, called hypersensitivity reactions, are classified 
according to the triggering mechanism (Table 5).
 The immediate hypersensitivity reactions (type I) are 
characterized by the presence of IgE and, generally, triggered 
by an external antigen (allergen). They may be systemic, 
involving multiple organs, or more restrictive as in urticaria 
and allergic rhinitis. The interaction between allergen and 
IgE preformed and prefixed to surface receptors of mast 
cells and basophils results in the release of soluble mediators 
(histamines) and synthesis of lipid mediators derived from 
arachidonic acid. Allergic rhinitis, asthma, and anaphylactic 
reactions are examples of type I reactions.
 Type II reactions depend on the production of antibodies 
(IgG and IgM classes) against a specific antigen. The fact that 
humoral response causes damage instead of protection depends 
on the nature of the antigen, imunglobulina isotype formed, 
and especially the specificity and avidity of the autoantibodies 
in question. The damage mechanisms associated with type II 
reactions include lysis of cells with antigen on their surface 
by activation of CS; destruction by NK cells, which have Fc 
receptors for IgG and perform antibody-mediated cytotoxicity; 
Table 5
Classification of hypersensitivity reactions 
according to Gell and Coombs
Type Alternative name Associated diseases Mediators
I Immediate 
hypersensitivity
Atopy
Anaphylaxis
Asthma
IgE
II Antibody-mediated 
hypersensitivity
Autoimmune 
hemolytic anemia
Goodpasture’s  disease
Erythroblastosis fetalis
IgG or IgM
and complement
III Immune complex-
mediated 
hypersensitivity
Serum sickness
Arthus’ Reaction
Lupus nephritis
IgG 
and complement
IV Delayed 
hypersensitivity
Transplant rejection
Contact dermatitis
Tuberculosis
T cells, 
macrophages, 
histiocytes
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and release of lytic enzymes and cytokines by neutrophils and 
macrophages activated by binding of Fc receptors to IgG. 
 Type III reactions are caused by the formation of antigen-
antibody immune complexes (IC), which are deposited in 
tissues and activate CS. The only antibodies involved are the 
ones capable of activating complement, IgM, IgA, and all IgG 
subclasses, except IgG4.
 Circulating IC is able to deposit in blood vessels, basement 
membrane of glomeruli and joints; and CS activation leads 
to tissue inflammation, which can result in rash, erythema 
nodosum, vasculitis, nephritis, arthritis, and pneumonitis. This 
type hypersensitivity reaction is found in various autoimmune 
diseases, such as lupus erythematosus, different types of 
vasculitis, and severe forms of rheumatoid arthritis.
Type IV reactions, or delayed type hypersensitivity, are 
mediated by TLs, macrophages, histiocytes, and monocytes. 
Cytotoxic T lymphocytes (CD8) cause direct tissue damage, 
while T-helper cells (CD4) secrete cytokines that recruit 
and activate cytotoxic TL, monocytes, and macrophages. 
Macrophages are responsible for the magnitude of tissue 
injury and granuloma formation characteristic of the infectious 
agent or foreign body persistency. Classic examples of type IV 
reaction are tuberculosis and leprosy in its tuberculoid form. 
Giant cell vasculitis and Takayasu’s arteritis also seem to arise 
from mechanisms related to type IV hypersensitivity.
PERSPECTIVES: INNATE IMMUNITY AND 
CHRONIC INFLAMMATORY DISEASES
The so-called autoimmune diseases, such as lupus erythematosus, 
rheumatoid arthritis, and systemic sclerosis are in fact chronic 
inflammatory disease of unknown etiology. The classification 
of these diseases as autoimmune derives mainly from the fact 
that they present high levels of circulating autoantibodies, 
although high levels of circulating autoantibodies also occur 
in some infectious diseases, cancers, and even in some normal 
individuals. For unknown reasons, the inflammatory process is 
perpetuated in these diseases. Over many decades, research has 
sought changes in adaptive immunity in autoimmune diseases. 
Lately, however, attention has been somewhat skewed to innate 
immunity, which ultimately coordinates the installation and 
ablation of any inflammatory process.
 As an example, it has been shown that mononuclear cells 
from peripheral blood of patients with SLE exhibit increased 
expression of genes related to type I interferon (IFN-α and 
IFN-β), typical mediators of innate response. Patients with 
active SLE show intense activity of interferon type I and, 
after controlling the disease, there is normalization of this 
parameter. This and other findings suggest that innate immunity 
disorders may be central in the pathophysiology of autoimmune 
diseases. As a corollary, the various elements involved in innate 
immunity may be interesting targets for biological therapy 
in these diseases. In fact, great efforts have been directed 
in recent years towards designing monoclonal antibodies 
and recombinant proteins capable of interacting with innate 
immunity elements and modulate inflammatory unwanted 
responses, seeking to regulate inflammatory responses in 
different exacerbated chronic inflammatory diseases.
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